Ciprofloxacin
General properties
Antibacterials for systemic use. The group of fluoroquinolones.
Uncomplicated and complicated infections caused by pathogens sensitive to ciprofloxacin.
- Respiratory Tract Infections: Ciprofloxacin can be recommended for the treatment of pneumonia caused by Klebsiella spp, Enterobacter spp, Proteus spp, Escherichia coli, Pseudomonas aeruginosa, Haemophilus spp, Moraxella catarrhalis, Legionella , and staphylococci.
- middle ear infections (otitis media) and paranasal sinuses (sinusitis), especially infections caused by gram-negative organisms, such as Pseudomonas aeruginosa,or staphylococci
- Eye Infections.
- kidney infections and / or urinary tract.
- Infections of the genital organs, including adnexitis, gonorrhea and prostatitis.
- abdominal infections (eg infections of the gastrointestinal tract, biliary tract, peritonitis).
- Infections of the skin and soft tissues.
- Infections of bones and joints.
- Sepsis.
- infection or a high risk of infection (prophylaxis) in patients with a weakened immune system (including during treatment with immunosuppressants and neutropenia).
- Selective intestinal decontamination during treatment with immunosuppressive agents.
- Prevention of invasive infections caused by Neisseria meningitidis.
Children. Ciprofloxacin can be used for children as a second and third line for the treatment of complicated urinary tract infections and pyelonephritis caused by Escherichia coli (in clinical studies age treated ranged from 1 to 17 years), as well as for the treatment of pulmonary complications caused by Pseudomonas aeruginosa in children with cystic fibrosis (in clinical trials of age treated ranged from 5 to 17 years).
Treatment with ciprofloxacin may be administered only after a careful assessment of the ratio of "risk-benefit" because of the likelihood of side effects from the joint and / or periarticular tissues.
The treatment of children in clinical trials carried out only on the testimony of the above. Clinical experience with children of ciprofloxacin for other indications is limited.
The inhalation form of anthrax in adults and children.
Reducing the risk of occurrence or progression of anthrax after aerogenic contact with Bacillus anthracis.
Hypersensitivity to ciprofloxacin or other quinolone chemotherapeutic agents and other ingredients; tizanidine simultaneous application of clinically significant side effects (hypotension, drowsiness) associated with an increase of the concentration of tizanidine in plasma; deficiency of glucose-6-phosphate dehydrogenase.
Pharmaceutical characteristics
Tablets of round shape, coated, white or white with a yellowish shade color, the upper and lower surfaces are convex. At the break can be seen under a magnifying glass core surrounded by a continuous layer.
Store in original packaging at a temperature not exceeding 25 oC. Keep out of the reach of children.
